SCHEMBL20053958

SCHEMBL20053958

COC(=O)CCN(S)c1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 1/20 0.40
HPGD P15428 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
TSHR P16473 2/20 0.38
GAA P10253 1/20 0.38
CYP1A2 P05177 2/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19557891 0.81 MTNR1A (0.42) MTNR1AMTNR1BALDH1A1MAPK1HPGD
SCHEMBL4269765 0.77 ALDH1A1 (0.48) MTNR1AMTNR1BALDH1A1MAPK1HPGD
SCHEMBL16793904 0.76 PTGER1 (0.56) ALDH1A1MAPK1LMNAKMT2ATSHR
SCHEMBL3448675 0.76 ALDH1A1 (0.47) MTNR1AMTNR1BALDH1A1MAPK1LMNA
SCHEMBL22350387 0.73 TP53 (0.47) MTNR1AMTNR1BALDH1A1LMNAKMT2A
SCHEMBL8399042 0.72 SMN1; SMN2 (0.39) MTNR1AMTNR1BALDH1A1MAPK1HPGD
SCHEMBL29970923 0.72 TAAR1 (0.53) CYP1A2L3MBTL1CYP3A4CYP2D6CYP2C19
SCHEMBL6378 0.72 TAAR1 (0.53) CYP1A2L3MBTL1CYP3A4CYP2D6CYP2C19
SCHEMBL16814117 0.71 MTNR1A (0.52) MTNR1AMTNR1BALDH1A1LMNAKDM4E
SCHEMBL18340892 0.71 L3MBTL1 (0.50) ALDH1A1MAPK1HPGDLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080103-B1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN MA INC (US) 2018-04-18 EP disclosed